Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
NTLAIntellia Therapeutics(NTLA) Zacks Investment Research·2024-02-24 01:16

Intellia Therapeutics, Inc. (NTLA) reported fourth-quarter 2023 loss of 1.46pershare,narrowerthantheZacksConsensusEstimateofalossof1.46 per share, narrower than the Zacks Consensus Estimate of a loss of 1.47. In the year-ago quarter, Intellia incurred a loss of 1.40pershare.Thecompany’stotalrevenuescurrentlycompriseonlycollaborationrevenues.NTLAreportednegativerevenuesof1.40 per share. The company’s total revenues currently comprise only collaboration revenues. NTLA reported negative revenues of 1.9 million during the fourth quarter of 2023 compared with 13.6millionreportedintheyear−agoquarter.ThetoplinemissedtheZacksConsensusEstimateof13.6 million reported in the year-ago quarter. The top line missed the Zacks Consensus Estimate of 15 million. The ...